Lenalidomide (hydrochloride)

• UNSPSC Description:

  Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator. Lenalidomide hydrochloride (CC-5013 hydrochloride) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hydrochloride (CC-5013 hydrochloride) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

• Target Antigen:

  Ligands for E3 Ligase; Molecular Glues

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Lenalidomide-hydrochloride.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O.[H]Cl

• Molecular Weight:

  295.72

• References & Citations:

  [1]Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.|[2]Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36.|[3]Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35.|[4]Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82.|[5]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.|[6]Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3(7):e941742.Food Chem Toxicol. 2019 Mar;125:392-402.|ACS Pharmacol Transl Sci. 2021 Feb 26.|Acta Pharmacol Sin. 2020 Sep;41(9):1246-1254.|Am J Pathol. 2015 Jun;185(6):1783-94. |Biochim Biophys Acta Mol Basis Dis. 2022 Jun 22;166472.|bioRxiv. 2024 June 12.|bioRxiv. 2024 October 19.|bioRxiv. April.|Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.|Cancer Res. 2024 Oct 22.|Cancer Sci. 2019 Dec;110(12):3802-3810.|Cancers (Basel). 2024 Mar 28, 16(7), 1319.|Cell Rep Med. 2024 Mar 19;5(3):101472.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell Rep. 2024 May 8;43(5):114211.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Cell. 2018 Sep 20;175(1):171-185.e25.|Clin Chim Acta. 2023 Dec 14:117707.|Elife. 2018 Aug 1;7:e38430. |Exp Cell Res. 2020 Aug 1;393(1):112054.|Faculty of Science, Masaryk University. Department of Experimental Biology.2014. |Food Chem Toxicol. 2019 Mar;125:392-402.|Free Radic Biol Med. 2023 Apr 10;S0891-5849(23)00373-8.|Front Cell Infect Microbiol. 2022 Jul 28;12:954814.|Harvard Medical School LINCS LIBRARY|Inflammation. 2019 Feb;42(1):221-234. |Int J Mol Sci. 2023 Sep 14, 24(18), 14097.|iScience. 19 July 2022, 104781.|Nat Cancer. 2022 May;3(5):595-613.|Nat Chem Biol. 2021 Jun;17(6):711-717.|Nat Commun. 2017 May 22;8:15398. |Nature. 2024 Sep;633(8030):670-677.|Oncol Rep. 2018 Jun;39(6):2873-2880. |Oxid Med Cell Longev. 29 Dec 2021.|Patent. US20170360780A1.|Patent. US20180263995A1.|Patent. US20210379039A1.|Patent. US20220332776A1.|Patent. US20240261246A1.|Universidad de Navarra. 2024 Feb 28.|University of Washington. The Columbian College of Arts and Sciences. August 31, 2021.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  1243329-97-6